Literature DB >> 7531628

Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia.

Y Amasaki1, S Kobayashi, T Takeda, N Ogura, S Jodo, T Nakabayashi, A Tsutsumi, A Fujisaku, T Koike.   

Abstract

Fas antigen (CD95) is a membrane-associated molecule that mediates apoptotic cell death and may play a role in the induction and maintenance of T cell tolerance. To elucidate the involvement of Fas antigen in human autoimmune diseases, we analysed Fas antigen expression by peripheral T cells from patients with SLE and rheumatoid arthritis (RA), using three-colour flow cytometry. Both CD4+ and CD8+ T cells from SLE patients expressed Fas antigen in a higher density than did these cells from healthy donors and from RA patients. Enhancement of Fas antigen density was noted in Fas+CD45RO+ memory T cells from SLE patients. More remarkably, a significant expression of Fas antigen was observed in CD45RO- naive T cells from SLE patients. CD4+CD45RO- T cells from SLE patients co-expressed Fas antigen and early to intermediate activation antigens such as CD25 and CD71, and late activation antigen HLA-DR in only FashiCD4+ naive T cells. Such up-regulation of Fas antigen expression in SLE patients seems to be clinically meaningful, because mean fluorescence intensity (MFI) of Fas antigen on CD4+ T cell subsets inversely correlates with the absolute size of CD4+ T cell subsets in peripheral blood of SLE patients. These results suggest that T cells with increased Fas antigen expression may be highly susceptible to apoptotic cell death, in vivo. A putative mechanism for lymphopenia in SLE patients is discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7531628      PMCID: PMC1534304          DOI: 10.1111/j.1365-2249.1995.tb05540.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood.

Authors:  T Miyawaki; T Uehara; R Nibu; T Tsuji; A Yachie; S Yonehara; N Taniguchi
Journal:  J Immunol       Date:  1992-12-01       Impact factor: 5.422

2.  Kinetics of anti-CD4-induced T helper cell depletion and inhibition of function. Activation of T cells by the CD3 pathway inhibits anti-CD4-mediated T cell elimination and down-regulation of cell surface CD4.

Authors:  I Jamali; E H Field; A Fleming; J S Cowdery
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

Review 3.  Apoptosis and programmed cell death in immunity.

Authors:  J J Cohen; R C Duke; V A Fadok; K S Sellins
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

4.  High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children.

Authors:  K M Debatin; A Fahrig-Faissner; S Enenkel-Stoodt; W Kreuz; A Benner; P H Krammer
Journal:  Blood       Date:  1994-05-15       Impact factor: 22.113

5.  Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice.

Authors:  M Adachi; R Watanabe-Fukunaga; S Nagata
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

6.  Transcriptional repression and differential splicing of Fas mRNA by early transposon (ETn) insertion in autoimmune lpr mice.

Authors:  S Kobayashi; T Hirano; M Kakinuma; T Uede
Journal:  Biochem Biophys Res Commun       Date:  1993-03-15       Impact factor: 3.575

7.  Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.

Authors:  A Oehm; I Behrmann; W Falk; M Pawlita; G Maier; C Klas; M Li-Weber; S Richards; J Dhein; B C Trauth
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

8.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.

Authors:  R Watanabe-Fukunaga; C I Brannan; N G Copeland; N A Jenkins; S Nagata
Journal:  Nature       Date:  1992-03-26       Impact factor: 49.962

9.  DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement.

Authors:  L B Owen-Schaub; S Yonehara; W L Crump; E A Grimm
Journal:  Cell Immunol       Date:  1992-03       Impact factor: 4.868

10.  Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis.

Authors:  N K Banda; J Bernier; D K Kurahara; R Kurrle; N Haigwood; R P Sekaly; T H Finkel
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

View more
  20 in total

Review 1.  Monitoring patients with HIV disease.

Authors:  M Helbert; J Breuer
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

2.  Effect of oestrogen on T cell apoptosis in patients with systemic lupus erythematosus.

Authors:  W-U Kim; S-Y Min; S-H Hwang; S-A Yoo; K-J Kim; C-S Cho
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

3.  Both perforin and FasL are required for optimal CD8 T cell control of autoreactive B cells and autoantibody production in parent-into-F1 lupus mice.

Authors:  Kateryna Soloviova; Maksym Puliaiev; Roman Puliaev; Irina Puliaeva; Charles S Via
Journal:  Clin Immunol       Date:  2018-06-22       Impact factor: 3.969

4.  Quantitative T cell subsets profile in peripheral blood from patients with idiopathic inflammatory myopathies: tilting the balance towards proinflammatory and pro-apoptotic subsets.

Authors:  F Espinosa-Ortega; D Gómez-Martin; K Santana-De Anda; J Romo-Tena; P Villaseñor-Ovies; J Alcocer-Varela
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

5.  Expression of IL-2R, IL-4R, IL-6R on peripheral blood lymphocytes in systemic lupus erythematosus and correlation with disease activity: a prospective study.

Authors:  E Y Chan; C S Lau; H Zola
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

6.  Soluble Fas molecule in the serum of patients with systemic lupus erythematosus.

Authors:  Y Tokano; S Miyake; N Kayagaki; K Nozawa; S Morimoto; M Azuma; H Yagita; Y Takasaki; K Okumura; H Hashimoto
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

7.  Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease.

Authors:  J Wu; J Wilson; J He; L Xiang; P H Schur; J D Mountz
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

Review 8.  The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus.

Authors:  Bernadete L Liphaus; Maria Helena Bittencourt Kiss
Journal:  Clinics (Sao Paulo)       Date:  2010-03       Impact factor: 2.365

9.  The type of responder T-cell has a significant impact in a human in vitro suppression assay.

Authors:  Srikanta Jana; Hope Campbell; Jeffrey Woodliff; Jill Waukau; Parthav Jailwala; Jugal Ghorai; Soumitra Ghosh; Sanja Glisic
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

10.  Fas (CD95) expression on CD4+ T cells from HIV-infected patients increases with disease progression.

Authors:  S P Aries; B Schaaf; C Müller; R H Dennin; K Dalhoff
Journal:  J Mol Med (Berl)       Date:  1995-12       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.